Federal Circuit revives Orexo’s opiate patent suit against Teva
11-09-2018
vladimirsorokin / iStockphoto.com
Pharmaceutical company Orexo has filed a complaint against Actavis Elizabeth and Teva Pharmaceuticals for infringing its patents covering Zubsolv (buprenorphine and naloxone).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Orexo, Actavis, Zubsolv, ANDA, FDA, generic, Teva
